POSLUMA Drug Patent Profile
✉ Email this page to a colleague
When do Posluma patents expire, and when can generic versions of Posluma launch?
Posluma is a drug marketed by Blue Earth and is included in one NDA. There is one patent protecting this drug.
This drug has seventeen patent family members in thirteen countries.
The generic ingredient in POSLUMA is flotufolastat f-18 gallium. One supplier is listed for this compound. Additional details are available on the flotufolastat f-18 gallium profile page.
DrugPatentWatch® Generic Entry Outlook for Posluma
Posluma will be eligible for patent challenges on May 25, 2027. This date may extended up to six months if a pediatric exclusivity extension is applied to the drug's patents.
By analyzing the patents and regulatory protections it appears that the earliest date
for generic entry will be May 25, 2028. This may change due to patent challenges or generic licensing.
Indicators of Generic Entry
Summary for POSLUMA
International Patents: | 17 |
US Patents: | 1 |
Applicants: | 1 |
NDAs: | 1 |
Finished Product Suppliers / Packagers: | 1 |
Drug Prices: | Drug price information for POSLUMA |
What excipients (inactive ingredients) are in POSLUMA? | POSLUMA excipients list |
DailyMed Link: | POSLUMA at DailyMed |
DrugPatentWatch® Estimated Loss of Exclusivity (LOE) Date for POSLUMA
Generic Entry Date for POSLUMA*:
Constraining patent/regulatory exclusivity:
NEW CHEMICAL ENTITY NDA:
Dosage:
SOLUTION;INTRAVENOUS |
*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.
Pharmacology for POSLUMA
Drug Class | Radioactive Diagnostic Agent |
Mechanism of Action | Positron Emitting Activity |
US Patents and Regulatory Information for POSLUMA
POSLUMA is protected by two US patents and one FDA Regulatory Exclusivity.
Based on analysis by DrugPatentWatch, the earliest date for a generic version of POSLUMA is ⤷ Try a Trial.
This potential generic entry date is based on NEW CHEMICAL ENTITY.
Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.
Patents protecting POSLUMA
Patent Number: ⤷ Try a Trial
Patent Expiration: ⤷ Try a Trial
Patented Use: POSITRON EMISSION TOMOGRAPHY (PET) OF PROSTATE-SPECIFIC MEMBRANE ANTIGEN (PSMA) POSITIVE LESIONS IN MEN WITH PROSTATE CANCER WITH SUSPECTED METASTASIS WHO ARE CANDIDATES FOR INITIAL DEFINITIVE THERAPY
Patent Number: ⤷ Try a Trial
Patent Expiration: ⤷ Try a Trial
Patented Use: POSITRON EMISSION TOMOGRAPHY (PET) OF PROSTATE-SPECIFIC MEMBRANE ANTIGEN (PSMA) POSITIVE LESIONS IN MEN WITH PROSTATE CANCER WITH SUSPECTED RECURRENCE BASED ON ELEVATED SERUM PROSTATE-SPECIFIC ANTIGEN (PSA) LEVEL
FDA Regulatory Exclusivity protecting POSLUMA
NEW CHEMICAL ENTITY
Exclusivity Expiration: ⤷ Try a Trial
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Blue Earth | POSLUMA | flotufolastat f-18 gallium | SOLUTION;INTRAVENOUS | 216023-001 | May 25, 2023 | RX | Yes | Yes | ⤷ Try a Trial | ⤷ Try a Trial | Y | ⤷ Try a Trial | |||
Blue Earth | POSLUMA | flotufolastat f-18 gallium | SOLUTION;INTRAVENOUS | 216023-001 | May 25, 2023 | RX | Yes | Yes | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | ||||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
International Patents for POSLUMA
See the table below for patents covering POSLUMA around the world.
Country | Patent Number | Title | Estimated Expiration |
---|---|---|---|
China | 111132700 | 双模放射性示踪剂与治疗剂 (Dual mode radiotracer and therapeutic agent) | ⤷ Try a Trial |
Mexico | 2020000352 | MARCADOR RADIOACTIVO DE MODO DUAL Y TERAPEUTICOS. (DUAL MODE RADIOTRACER AND -THERAPEUTICS.) | ⤷ Try a Trial |
European Patent Office | 3658194 | AGENTS À DEUX MODES RADIOTRACEURS ET THÉRAPEUTIQUES (DUAL MODE RADIOTRACER AND -THERAPEUTICS) | ⤷ Try a Trial |
Brazil | 112020001785 | radiotraçador e compostos radioterapêuticos bimodais | ⤷ Try a Trial |
Japan | 2020528461 | デュアルモードの放射性トレーサーおよび療法剤 | ⤷ Try a Trial |
>Country | >Patent Number | >Title | >Estimated Expiration |